Lancet 2021 06 3;397(10292):2331-2333. Epub 2021 Jun 3.
Francis Crick Institute, London, UK. Electronic address:
J Mol Graph Model 2021 Jul 13;108:107984. Epub 2021 Jul 13.
Department of Internal Medicine, Children's Hospital of Wujiang District, Suzhou 215200, China. Electronic address:
Human respiratory syncytial virus (RSV) is the major cause of acute lower respiratory tract infections worldwide in infants and young children. The RSV F glycoprotein is a class I fusion protein that mediates viral entry into host cells and is a major target of neutralizing antibodies. Targeting F glycoprotein has been recognized as a promising antiviral therapeutic strategy against RSV infection. Read More
Curr Opin Immunol 2021 Jul 23;71:103-110. Epub 2021 Jul 23.
Dept. of Rheumatology and Clinical Immunology and Center for Chronic Immunodeficiency, Medical Center, University of Freiburg, Freiburg, Germany. Electronic address:
The BAFF-receptor (BAFFR) is a member of the TNF-receptor family. It is expressed only by B cells and binds BAFF as single ligand, which activates key signaling pathways regulating essential cellular functions, including survival, protein synthesis, and metabolic fitness. In humans, BAFFR deficiency interrupts B cell development at the transition from immature to mature B cells and causes B lymphopenia, hypogammaglobulinemia, and impaired humoral immune responses. Read More
Cell Mol Gastroenterol Hepatol 2021 Jul 23. Epub 2021 Jul 23.
Department of Medicine, Gastroenterology and Hepatology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address:
Background & Aims: The epithelial barrier is the host's first line of defense against damage to the underlying tissue. Upon injury, the epithelium plays a critical role in inflammation. The IKKβ/NF-κB pathway was shown to be active in the esophageal epithelium of patients with esophageal disease. Read More
PLoS One 2021 26;16(7):e0253551. Epub 2021 Jul 26.
Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.
Background: The novel coronavirus SARS-CoV2 that causes COVID-19 has resulted in the death of more than 2.5 million people, but no cure exists. Although passive immunization with COVID-19 convalescent plasma (CCP) provides a safe and viable therapeutic option, the selection of optimal units for therapy in a timely fashion remains a barrier. Read More
Curr Opin HIV AIDS 2021 Jul 23. Epub 2021 Jul 23.
Fundació Lluita Contra La Sida, Infectious Diseases Department IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias I Pujol Centre for Health and Social Care Research (CESS), Faculty of Medicine. University of Vic - Central University of Catalonia (UVic - UCC) ICREA AELIX Therapeutics, Barcelona, Spain.
Purpose Of Review: In this special issue on human immunodeficiency (HIV) cure, we review the role of therapeutic immunization in strategies aimed to eliminate HIV-infected cells and/or mediate sustained control of viral replication in the absence of antiretroviral treatment.Recent Findings: Recent data emerging from studies in simian immunodeficiency virus macaque models using broadly neutralizing antibodies, given alone or in combination with other immunomodulatory agents, as well as data from human clinical studies with novel therapeutic vaccines are showing encouraging results indicating that achieving viral remission or at least partial viral control of HIV without antiretroviral therapy is feasible.Summary: Although it remains unclear whether current strategies will be able to awaken a sufficient large fraction of the viral reservoir and/or vaccine-boosted immunity will induce effective, long-lasting viral suppression in chronically infected HIV population, emerging results establish cure strategies that can be further improved upon. Read More